Abstract:Myasthenia gravis (MG) is an autoimmune disease characterized by dysfunction of the neuromuscular junction resulting in skeletal muscle weakness. It is equally prevalent in males and females, but debuts at a younger age in females and at an older age in males. Ptosis, diplopia, facial bulbar weakness, and limb weakness are the most common symptoms. MG can be classified based on the presence of serum autoantibodies. Acetylcholine receptor (AChR) antibodies are found in 80%-85% of patients, muscle-specific kinase (MuSK) antibodies in 5%-8%, and <1% may have low-density lipoprotein receptor-related protein 4 (Lrp4) antibodies. Approximately 10% of patients are seronegative for antibodies binding the known disease-related antigens. In patients with AChR MG, 10%-20% have a thymoma, which is usually detected at the onset of the disease. Important differences between clinical presentation, treatment responsiveness, and disease mechanisms have been observed between these different serologic MG classes. Besides the typical clinical features and serologic testing, the diagnosis can be established with additional tests, including repetitive nerve stimulation, single fiber EMG, and the ice pack test. Treatment options for MG consist of symptomatic treatment (such as pyridostigmine), immunosuppressive treatment, or thymectomy. Despite the treatment with symptomatic drugs, steroid-sparing immunosuppressants, intravenous immunoglobulins, plasmapheresis, and thymectomy, a large proportion of patients remain chronically dependent on corticosteroids (CS). In the past decade, the number of treatment options for MG has considerably increased. Advances in the understanding of the pathophysiology have led to new treatment options targeting B or T cells, the complement cascade, the neonatal Fc receptor or cytokines. In the future, these new treatments are likely to reduce the chronic use of CS, diminish side effects, and decrease the number of patients with refractory disease.

Advances in the Pathogenesis of Thymus and Myasthenia Gravis

Advances in Immunopathogenesis and Treatment of Myasthenia Gravis

Advances in Understanding and Managing Myasthenia Gravis: Current Trends and Future Directions

Non-neuronal cholinergic activity is potentiated in myasthenia gravis

The role of innate immunity in myasthenia gravis

Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms

Myasthenia gravis-Pathophysiology, diagnosis, and treatment

Myasthenia Gravis: Novel Findings and Perspectives on Traditional to Regenerative Therapeutic Interventions

Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations

Augmentation Of Circulating Follicular Helper T Cells And Their Impact On Autoreactive B Cells In Myasthenia Gravis

B cells in the pathophysiology of myasthenia gravis

Mitochondrial dysfunction in myasthenia gravis: Exploring directions for future immunotherapy? A review

Advances of Speciifc Targeting Immunotherapy in Myasthenia Gravis

Myasthenia gravis: Molecular mechanisms and promising therapeutic strategies

Myasthenia gravis: the future is here

Establishment of a Mouse Model of Experimental Autoimmune Myasthenia Gravis

Increase of circulating CD4 +CD25 + T cells in myasthenia gravis patients with stability and thymectomy

[Recent advance in research for myasthenia gravis, in relation to various antibodies affecting synaptic structure and function]

Decrease of CD4+CD25highFoxp3+ regulatory T cells and elevation of CD19+BAFF-R+ B cells and soluble ICAM-1 in myasthenia gravis

Research Progress of Myasthenia Gravis and Cytokines

The present status and problems of multi-target therapy of myasthenia gravis